Libya vs Norway: HIV/AIDS deaths averted by antiretroviral therapy
Libya
164.5 deaths
in 2024
Norway
168.96 deaths
in 2024
Libya rank
114th
Norway rank
113th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Libya
- Norway
How they compare
Norway currently reports 168.96 deaths against 164.5 deaths in Libya, a difference of 4.46 deaths.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Norway ahead.
Libya ranks 114th and Norway ranks 113th of 157 countries.
Across the 4 decades both report, Libya averaged higher in 1 and Norway in 3.
Head to head by decade
| Decade | Libya | Norway | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 24.26 deaths | 24.26 deaths | Norway |
| 2000s | 58.07 deaths | 111.82 deaths | 53.74 deaths | Norway |
| 2010s | 191.14 deaths | 182.68 deaths | 8.46 deaths | Libya |
| 2020s | 175.32 deaths | 180.2 deaths | 4.88 deaths | Norway |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Libya or Norway?
- Norway, at 168.96 deaths against 164.5 deaths in Libya as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Libya and Norway?
- 4.46 deaths, with Norway ahead.
- How many years of comparable data are there for Libya and Norway?
- 35 years are reported by both, from 1990 to 2024.
- How do Libya and Norway rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Libya ranks 114th and Norway ranks 113th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.